In Ewing sarcoma, we previously documented that the inhibition of the mTOR/AKT/PI3K pathway sets in motion an hnRNPM-dependent alternative splicing program that limits the therapeutic efficacy of these pharmacologic inhibitors [24]. The gene discussed is AKT1; the disease is Ewing sarcoma.